Sun Pharma’s Q3FY22 operational performance was in line with I-direct estimates with sustained momentum and good growth across businesses
Sun Pharmaceutical Industries has reported consolidated financial results for the period ended December 31, 2021
CEQUA’s nanomicellar (NCELL) technology improves the bioavailability and physicochemical stability of cyclosporine to increase ocular tissue penetration
The product is expected to be available in a week’s time
The Drug Controller General of India (DCGI), is reviewing clinical data of molnupiravir for the treatment of Covid-19 in adults in India
Sun Pharma has reported consolidated financial results for the period ended September 30, 2021.
It is the first U.S. FDA approved novel topical mechanism for acne in nearly 40 years
Moderate-to-severe plaque psoriasis affects about 35 per cent of patients. A key challenge is that many treatments stop working overtime and symptoms return
Chericof 12, the first prescription cough syrup in India which gives relief for up to 12 hours, is manufactured using Polistirex technology for sustained release of the drug
The company said Revital NXT is India’s first nutrition bar with the goodness of natural ginseng, 16 vitamins & minerals and triple blend protein
Subscribe To Our Newsletter & Stay Updated
